

Available this Fall!

Help protect infants from RSV in their first season, with Beyfortus®

 **Beyfortus®**
(nirsevimab)

Before RSV.

What is Beyfortus® used for?

Beyfortus® protects your baby from getting respiratory syncytial virus (RSV) disease in their first RSV season. It may also be given to children less than 2 years of age who are vulnerable to severe RSV disease in their second RSV season.

How does Beyfortus® work?

Beyfortus® contains the active ingredient nirsevimab, which is a long-acting antibody that blocks the protein that RSV needs to infect the body. Beyfortus® stops the virus from entering and infecting human cells and provides direct and timely protection against RSV disease to last for at least 5 months, corresponding to a typical RSV season.

Questions for your doctor



To help you have an informed discussion about RSV and protection for your infant with Beyfortus®, here are some questions that you may wish to discuss with your healthcare professional. This PDF can be downloaded and printed out to bring with you as reference to your next visit.

- What are some other steps I can take to help protect my infant from getting RSV?
- Is there a way to predict whether my infant's RSV infection will be mild or serious?
- How can Beyfortus® help protect my infant from RSV?

Ask your healthcare professional if Beyfortus® is right for your child. 100% protection cannot be guaranteed. Uncommon side effects (may affect up to 1 in 100 children) can include rash, injection site reaction and fever. Full product information can be found on [Sanofi.ca](https://www.sanofi.ca). To report an adverse event, please call 1-866-234-2345.

You can also find the full product monograph, which is prepared for healthcare professionals and includes the complete Patient Medication Information, by visiting the manufacturer's website: <https://www.sanofi.com/assets/countries/canada/docs/products/vaccines/beyfortus-en.pdf> or by calling 1-800-265-7927.

sanofi

Sanofi & AstraZeneca are collaborating on the development and commercialization of Beyfortus®.
© 2023 Sanofi Pasteur Limited. All rights reserved.
Do not use this piece after 30/09/2025 as some of the information may be outdated.

MAT-CA-2301157E-v1.0-09/2023

 MEMBER OF
INNOVATIVE MEDICINES CANADA

